Question special
Chief Resident

It would be interesting to know the safety and efficacy data of Dapagliflozin among different age groups; would elderly patients be able to tolerate the drug as well as younger patients? The results of the trial are really fascinating and SGLTi are probably going to be indicated for HF independent of diabetes status.